Medical Director Articles

The term "article" is used to describe any bulletin article, web site article, educational handout or any other non-LCD document intended for public release that contains coverage/coding statements or medical review related billing or claims considerations.

Articles address local coverage, coding or medical review related billing and claims considerations, and may include any newly developed educational materials, coding instructions or clarification of existing medical review related billing or claims policy.

The article listing will continue to expand as additions are made.

Last Updated Jan 30 , 2024
Articles Source Posted
Billing and Coding: MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer (A57329) - R5 - Effective February 24, 2022 Oct 02, 2025
MolDX: Pharmacogenomics Testing (L38335) - R3 - Effective October 2, 2025 Oct 02, 2025
Billing and Coding: MolDX: Pharmacogenomics Testing (A57384) - R17 - Effective July 3, 2025 Oct 02, 2025
Billing and Coding: MolDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR) (A57423) - R5 - Effective November 7, 2024 Oct 02, 2025
Billing and Coding: MolDX: MGMT Promoter Methylation Analysis (A57432) - R3 - Effective October 14, 2021 Oct 02, 2025
Billing and Coding: MolDX: Oncotype DX Breast Cancer Assay (A54480) - R5 - Effective November 1, 2019 Oct 02, 2025
Policy Revision(s) for Multiple Billing and Coding Articles - Effective October 2, 2025 Oct 02, 2025
Billing and Coding: Implantable Infusion Pumps for Chronic Pain (A55239) - R22 - Effective October 1, 2025 Oct 02, 2025
2025 ICD-10 Billing and Coding Article Updates - Effective October 1, 2025 Oct 02, 2025
Self-Administered Drug Exclusion List (A53032) - R43 - Effective November 15, 2025 Oct 02, 2025
Multi-Jurisdictional Contractor Advisory Committee (CAC) Meeting Announcement - Implantation of Anterior Segment Intraocular Nonbiodegradable Drug-eluting System - November 12, 2025, 2 - 4 pm CT Sep 26, 2025
Billing and Coding: MolDX: Pigmented Lesion Assay (A58052) - R3 - Effective December 23, 2021 Sep 25, 2025
Billing and Coding: MolDX: Plasma-Based Genomic Profiling in Solid Tumors (A58973) - R10 - Effective July 1, 2025 Sep 25, 2025
Billing and Coding: MolDX: Prometheus IBD sgi Diagnostic Policy (A57516) - R4 - Effective October 20, 2022 Sep 25, 2025
Billing and Coding: Pulmonary Rehabilitation Services (A56152) - R8 - Effective October 1, 2023 Sep 25, 2025
Billing and Coding: MolDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML) (A55711) - R7 - Effective June 1, 2023 Sep 25, 2025
Billing and Coding: MolDX: Oncotype DX Colon Cancer (A54484) - R4 - Effective November 1, 2019 Sep 25, 2025
Billing and Coding: Single Chamber and Dual Chamber Permanent Cardiac Pacemakers - Coding and Billing (A54929) - R12 - Effective October 1, 2023 Sep 25, 2025
Proposed LCDs - Published for Review and Comments Sep 25, 2025
Open Public Meeting Announcement Multiple LCDs - October 30, 2025 Sep 25, 2025
Policy Revision(s) for Multiple Billing and Coding Articles - Effective September 25, 2025 Sep 25, 2025
MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms (L39923) - R1 - Effective July 3, 2025 Sep 25, 2025
Billing and Coding: MolDX: Genetic Testing in Heritable Thoracic Aortic Disease (A59868) - R1 - Effective August 17, 2025 Sep 25, 2025
Billing and Coding: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (A59872) - R1 - Effective August 17, 2025 Sep 25, 2025
Self-Administered Drugs - Process to Determine Which Drugs Are Not Usually Self-administered By the Patient (A53893) - R3 - Effective October 1, 2015 Sep 18, 2025
Local Coverage Determination (LCD) Finalized - Effective November 2, 2025 Sep 18, 2025
Micro Invasive Glaucoma Surgery L38299 - R6 - Effective November 17, 2024 Sep 18, 2025
Billing and Coding: Billing Limitations for Pharmacies (A56119) Retirement - Effective September 18, 2025 Sep 18, 2025
Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) Final LCD - Effective October 26, 2025 Sep 11, 2025
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720) - R29 - Effective October 1, 2025 Sep 11, 2025
Policy Revision(s) for Local Coverage Determinations and Associated Billing and Coding Articles - Effective September 11, 2025 Sep 11, 2025
Billing and Coding: MolDX: Germline testing for use of PARP inhibitors (A55294) - R12 - Effective October 1, 2025 Sep 04, 2025
Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer (A58679) - R9 - Effective October 1, 2025 Sep 04, 2025
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R13 - Effective October 1, 2025 Sep 04, 2025
Billing and Coding: MolDX: Biomarkers in Cardiovascular Risk Assessment (A57037) - R7 - Effective October 1, 2025 Aug 28, 2025
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720) - R27 - Effective October 1, 2025 Aug 28, 2025
MolDX Open Public Meeting Announcement Multiple LCDs - October 8, 2025 Aug 28, 2025
Proposed LCDs - Published for Review and Comments Aug 28, 2025
MolDX: HLA-DQB1*06:02 Testing for Narcolepsy (L36551) - R5 - August 24, 2023 Aug 21, 2025
MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease (L36180) - Retirement - Effective August 17, 2025 Aug 21, 2025
Policy Revision(s) for Local Coverage Determinations and Associated Billing and Coding Articles - Effective August 14, 2025 Aug 14, 2025
Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT) (A57526) - R24 - Effective August 14, 2025 Aug 14, 2025
Billing and Coding: MolDX: Proteomics Testing (A59641) - R10 - Effective August 14, 2025 Aug 14, 2025
MolDX: MGMT Promoter Methylation Analysis (L36188) - R6 - Effective August 7, 2025 Aug 07, 2025
MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis (L39467) - R2 - Effective August 7, 2025 Aug 07, 2025
Billing and Coding: Micro-Invasive Glaucoma Surgery (MIGS) (A57863) - R8 - Effective November 17, 2024 Jul 31, 2025
Billing and Coding: Artificial Hearts and Percutaneous Endovascular Cardiac Assist Procedures and Devices (A59657) - R2 - September 30, 2024 Jul 31, 2025
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R12 - Effective July 31, 2025 Jul 31, 2025
Billing and Coding: Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea (A57948) - R6 - Effective January 1, 2025 Jul 24, 2025
Billing and Coding: MolDX: Molecular Testing for Solid Organ Allograft Rejection (A58168) - R11 - Effective July 24, 2025 Jul 24, 2025
Multi-Jurisdictional CAC Meeting Announcement - Cardiac Percutaneous Lithotripsy - August 20, 2025, 2:30 pm - 4:30 pm CT Jul 24, 2025
Multi-Jurisdictional Contractor Advisory Committee (CAC) Coronary Intravascular Lithotripsy (IVL) - Key Questions Jul 24, 2025
Multi-Jurisdictional Contractor Advisory Committee (CAC) Coronary Intravascular Lithotripsy (IVL) - Bibliography Jul 24, 2025
Multi-Jurisdictional Contractor Advisory Committee (CAC) Coronary Intravascular Lithotripsy (IVL) - Agenda Jul 24, 2025
Updates to JE/JF Local Coverage Determinations (LCDs) and Billing and Coding Articles (BCAs) Jul 22, 2025
Policy Revision for Local Coverage Determination Facet Joint Interventions for Pain Management - Effective July 17, 2025 Jul 17, 2025
Open Meeting Announcement - MolDX: Molecular Testing for Solid Organ Allograft Rejection - August 26, 2025 Jul 17, 2025
Open Meeting Announcement - MolDX: Biomarker Testing for Risk Stratification in DCIS - August 27, 2025 Jul 17, 2025
MolDX: Molecular Testing for Solid Organ Allograft Rejection - Published for Review and Comments Jul 17, 2025
MolDX: Biomarker Testing for Risk Stratification in DCIS - Published for Review and Comments Jul 17, 2025
Multi-Jurisdictional CAC Meeting Announcement - MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, Neoplasia - September 4, 2025, 1 - 3 p.m. CT Jul 17, 2025
Multi-Jurisdictional CAC Meeting Announcement - MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, Neoplasia: Agenda Jul 17, 2025
Billing and Coding: MolDX: Plasma-Based Genomic Profiling in Solid Tumors (A58973) - R9 - Effective July 1, 2025 Jul 10, 2025
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R11 - Effective July 1, 2025 Jul 10, 2025
MolDX: Molecular Testing for Solid Organ Allograft Rejection (L38629) - R1 - Effective July 10, 2025 Jul 10, 2025
Billing and Coding Investigational Device Exemptions (IDE) - IDE Documentation Requirements for Studies with an FDA Approval dated January 01, 2015, or later (A54919) - R8 - Effective October 1, 2015 Jul 03, 2025
2025 Q3 MolDX CPT/HCPCS Billing and Coding Article Updates - Effective July 1, 2025 Jul 03, 2025
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720) - R26 - Effective July 1, 2025 Jul 03, 2025
Billing and Coding: MolDX: Pharmacogenomics Testing (A57384) - R16 - Effective July 1, 2025 Jul 03, 2025
MolDX: Breast Cancer Index (BCI) Gene Expression Test (L37822) - R5 - Effective July 3, 2025 Jul 03, 2025
MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer (L39005) - R2 - Effective July 3, 2025 Jul 03, 2025
MolDX: Pharmacogenomics Testing (L38335) - R2 - Effective July 3, 2025 Jul 03, 2025
MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells (L38643) - R2 - Effective July 3, 2025 Jul 03, 2025
MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer (L38327) - R3 - Effective July 3, 2025 Jul 03, 2025
MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer (L38647) - R2 - Effective July 3, 2025 Jul 03, 2025